[u'Average Duration of Effect', u'Clinical Comment', u'Prescribing Recommendations', u'Table 5 Effects on steady-state fexofenadine pharmacokinetics after 7 days of co-administration with fexofenadine hydrochloride 120 mg every 12 hours in healthy adult subjects (n=24)', u'Ratio (with/without coadministered drug) of Indinavir Pharmacokinetic Parameters (90% CI); No Effect = 1.00', u'Ratio (with/without CRIXIVAN) of Coadministered Drug Pharmacokinetic Parameters (90% CI); No Effect = 1.00', u'Risperidone\xc2\xa0Dose Recommendation', u'Effect', u'Digoxin concentrations increased > 50%', u'Caution\xc2\xa0should\xc2\xa0be\xc2\xa0exercised\xc2\xa0when\xc2\xa0combining\xc2\xa0digoxin\xc2\xa0with\xc2\xa0any drug that may cause significant deterioration in renal function (e.g., ACE inhibitors, angiotensin receptor blockers, nonsteroidal anti-inflammatory drugs [NSAIDs], COX-2 inhibitors) since a decline in glomerular filtration or tubular secretion may impair the excretion of digoxin.', u'Inducers', u'Specific Drugs', u'VIAGRA 25 mg', u'', u'VIAGRA 100 mg', u'Recommendation', u'ClinicalComment', u'hyperthyroidism', u'hypothyroidism', u'nizatidine', u'Interaction', u'CLINICAL EFFECT(S)', u'Recommendations for Voriconazole Dosage Adjustment/Comments', u'Recommendations for Drug Dosage Adjustment/Comments', u'Systemic exposure to these drugs is increased significantly by the addition of ketoconazole: Concomitant use with ketoconazole is contraindicated.', u'Systemic exposure to ketoconazole is reduced significantly by these drugs: Concomitant use with ketoconazole is not recommended.', u'mebendazole', u'Cmax of Didanosine (90% CI)', u'\xe2\u2020\u201d Indicates no change, or mean increase or decrease of less than 10%.', u'Drugs With Clinical Recommendations Regarding Coadministration (see PRECAUTIONS , Drug Interactions )', u'No Clinically Significant Interaction Observed', u'* The interaction between immediate-release VIRAMUNE and the drug was evaluated in a clinical study. The results of drug interaction studies with immediate-release VIRAMUNE are expected to also apply to VIRAMUNE XR.', u"a) Predictions are based on BANZEL concentrations at the maximum recommended dose of BANZEL. b) Maximum changes predicted to be in children and in patients who achieve significantly higher levels of BANZEL, as the effect of rufinamide on these AEDs is concentration-dependent. c) Larger effects in children at high doses/concentrations of AEDs. d) Phenobarbital, primidone and phenytoin were treated as a single covariate (phenobarbital-type inducers) to examine the effect of these agents on BANZEL clearance. e) All compounds of the benzodiazepine class were pooled to examine for 'class effect' on BANZEL clearance.", u'Dosage Adjustment', u'\xe2\u2020\u201c = Decreased (induces lamotrigine glucuronidation).', u'% Change from Plavix (300 mg/75 mg) alone', u'Platelet Inhibition Inhibition of platelet aggregation with 5 mcM ADP (%)', u'Day 5', u'AUCss (0-12h) (Extent of systemic exposure)', u'Risperidone Dose Recommendation', u'I. Due to the competition of salicylate with other drugs for binding to serum albumin the following drug interactions may occur:', u'Table 4. Established and Other Potentially Significant Drug Interactions', u'AUC SS (0\xe2\u20ac\u201c12h) (Extent of systemic exposure)', u'Influence of AED on MHD Concentration (Mean Change, 90% Confidence Interval)', u'Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis ( 2.6 , 5.1 , 7 , 12.3 )', u'Topiramate Concentration', u'Concomitant administration with digoxin was associated with a higher rate of torsades de pointes.', u'Risperidone DoseRecommendation', u'Cmax', u'AUC ss(0-12h ) (Extent of systemic exposure)', u'TOPAMAX Concentration', u'Clinical\xc2\xa0Comment', u'\xe2\u2020\u2018 Indicates increase. \xe2\u2020\u201c Indicates decrease.', u'\xe2\u2020\u2018 Indicates increase.', u'Table 7 Summary of AED Interactions with Oxcarbazepine', u'*Refer to PRECAUTIONS, Drug Interactions for information regarding table.', u'AUC ss(0-12h) (Extent of systemic exposure)', u'Gastrointestinal Agents', u'Other Drugs', u'Other Drugs/Dietary Supplements', u'*Change relative to reference', u'*Not administered but an\t\t\t\t\t\t\t\t\t\t\t\tactive metabolite of carbamazepine.', u'Avoid atorvastatin', u'a = Plasma concentration increased 25% in some patients, generally those on a twice a day dosing regimen of phenytoin. b =\xc2\xa0Is not administered but is an active metabolite of carbamazepine. NC = Less than 10% change in plasma concentration. NE = Not Evaluated.', u'Storage', u'\xe2\u2020\u201c= Decreased (induces lamotrigine glucuronidation). \xe2\u2020\u2018= Increased (inhibits lamotrigine glucuronidation). ?= Conflicting data.', u'Dosing of Vardenafil 5 mg and Alpha-Blocker Separated by 6 Hours, Placebo-Subtracted', u'Vardenafil 20 mg Placebo-subtracted', u'* Refer to PRECAUTIONS, Drug Interactions for information regarding table.', u'Topiramate\xc2\xa0Concentration', u'Effect\xe2\u20ac', u'Gastrointestinal Agents cimetidine ranitidine Immunosuppressives tacrolimus Other Drugs fibric acid derivatives (e.g., bezafibrate, fenofibrate)', u'Table 2: Drug-Thyroidal Axis Interactions', u'Comments', u'Table IV. Drugs that have been documented not to interact with theophylline or drugs that produce no clinically significant interaction with theophylline. Refer to PRECAUTIONS, Drug Interactions for information regarding table.', u'Digoxin concentrations increased greater than 50%', u'A\xc2\xa0decline\xc2\xa0in\xc2\xa0GFR\xc2\xa0or\xc2\xa0tubular\xc2\xa0secretion,\xc2\xa0as\xc2\xa0from\xc2\xa0ACE\xc2\xa0inhibitors, angiotensin receptor blockers, nonsteroidal anti-inflammatory drugs [NSAIDs], COX-2 inhibitors may impair the excretion of digoxin.', u'Clinical Comments', u'SUPRANE (desflurane, USP) MAC with Fentanyl or Midazolam Mean \xc2\xb1 SD (percent reduction)', u'Dosage of Muscle Relaxant Causing 95% Depression in Neuromuscular Blockade', u'Observed Drug Interactions', u'Influence of AED on MHD Concentration (Mean change, 90% Confidence Interval)', u'Table 4 Drugs Tested in In Vitro Binding or In Vivo Drug Interaction Testing or With Post-Marketing Reports', u'Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis ( 2.2 , 4 , 5.2 , 7.1 , 7.2 , 7.3 , 7.4 , 12.3 )', u'EFFECT', u'\xe2\u2020\u201c= Decreased (induces lamotrigine gluronidation). \xe2\u2020\u2018= Increased (inhibits lamotrigine gluronidation). ?= Conflicting data.', u'Table 7: Summary of AED Interactions with Oxcarbazepine', u'a = Plasma concentration increased 25% in some patients, generally those on a twice a day dosing regimen of phenytoin. b = Is not administered but is an active metabolite of carbamazepine. NC = Less than 10% change in plasma concentration. NE = Not Evaluated', u'Examples of Drugs', u'DESCRIPTION OF INTERACTION', u'EFFECT OF SALICYLATES', u'Description of Interaction', u'Description', u'Effect of Salicylates', u'NA - Not Available * - 90% Confidence interval not reported Mean rifabutin concentrations one-half day after the last dose of rifabutin were 60 ng/mL when coadministered with azithromycin and 71 ng/mL when coadministered with placebo.', u'NA \xe2\u20ac\u201c Not available * - 90% Confidence interval not reported Mean azithromycin concentrations one day after the last dose were 53 ng/mL when coadministered with 300 mg daily rifabutin and 49 ng/mL when coadministered with placebo.', u'Table 2: Drug \xe2\u20ac\u201d Thyroidal Axis Interactions', u'Drug plasma concentration increased by itraconazole', u'roxithromycin', u'Other Drugs / Dietary Supplements', u'* The interaction between VIRAMUNE and the drug was evaluated in a clinical study. All other drug interactions shown are predicted.', u'* Change relative to reference', u'* The interaction between nevirapine and the drug was evaluated in a clinical study. All other drug interactions shown are predicted.', u'Drugs that may reduce TSH secretion -the reduction is not sustained; therefore, hypothyroidism does not occur', u'lomefloxacin', u'Strong CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, fluoxetine) inhibitors will increase ABILIFY drug concentrations; reduce ABILIFY dose by one-half when used concomitantly (2.6 , 7.1) , except when used as adjunctive treatment with antidepressants (2.6) CYP3A4 inducers (eg, carbamazepine) will decrease ABILIFY drug concentrations; double ABILIFY dose when used concomitantly (2.6 , 7.1)', u'InteractionInteraction', u'a = Plasma concentration increased 25% in some patients, generally those on a twice a day dosing regimen of phenytoin.', u'Other Drugs/DietarySupplements', u'AUC ss(0\xe2\u20ac\u201c12h) (Extent of systemic exposure)', u'*\xc2\xa0 Refer to PRECAUTIONS, Drug Interactions for information regarding table.', u'*Refer to for information regarding table. PRECAUTIONS, Drug Interactions', u'Prescribing\xc2\xa0Recommendations', u'a = Plasma concentration increased 25% in some patients, generally those on a b.i.d. dosing regimen of phenytoin. b = Is not administered but is an active metabolite of carbamazepine. NC = Less than 10% change in plasma concentration. AED = Antiepileptic drug. NE = Not Evaluated. TPM = Topiramate', u'hyperthyroidism poor nutritional state steatorrhea vitamin K deficiency', u'Classes of Drugs', u'Specific Drugs Reported', u'hypothyroidism nephrotic syndrome', u'HIV Antiviral Agents: Reverse Transcriptase Inhibitors', u'2C19', u'Effects of Salicylates', u'Other Drugs / Dietary Supplements bosentan octreotide orlistat St. John\xe2\u20ac\u2122s Wort sulfinpyrazone terbinafine ticlopidine', u'DRUG INTERACTIONS', u'Table III. Drugs That Have Been Documented Not to Interact With Theophylline or Drugs That Produce No Clinically Significant Interaction With Theophylline*', u'pimozide', u'Salmonella/Microsome Test (Negative)', u'Rat Hepatocyte DNA Repair Assay', u'nizatidinenorfloxacin', u'\xe2\u2020\u201c\xc2\xa0= Decreased (induces lamotrigine gluronidation). \xe2\u2020\u2018\xc2\xa0= Increased (inhibits lamotrigine glucuronidation). ? = Conflicting data.', u'1 nc denotes a mean change of less than 10%', u'a) This table is not all inclusive.', u'DISCRIPTION OF INTERACTION', u'Possible Mechanism', u'Mean (\xc2\xb1SD)', u'Mean (\xc2\xb1 SD)', u'Recommendations', u'Effects on Steady-State Fexofenadine Pharmacokinetics After 7 Days of Co-Administration with Fexofenadine Hydrochloride 120 mg Every 12 Hours (two times the recommended twice daily dose) in Healthy Volunteers (n=24)', u'3-Hydroxydesloratadine', u'1 Mean \xc2\xb1 (\xce\xbcg/g)', u'Clinical Recommendations', u'Prescribing Recommendations for LIPTRUZET', u'Effect Average effect on steady state theophylline concentration or other clinical effect for pharmacologic interactions. Individual patients may experience larger changes in serum theophylline concentration than the value listed.', u'medroxyprogesterone', u'Clarithromycin + Omeprazole', u'\xe2\u2020\u2018Indicates increase. \xe2\u2020\u201cIndicates decrease.', u'*Range', u'*First-dose values; all other parameters are last-dose values', u'1 nc denotes a mean change of less than 10% 2 Pediatrics 3 Mean increase in adults at high oxcarbazepine doses', u'ciprofloxacin, gentamicin, tobramycin, vancomycin, trimethoprim with sulfamethoxazole', u'azithromycin, clarithromycin, erythromycin, quinupristin/dalfopristin', u'nafcillin, rifampin', u'Increased Risk of Myopathy/Rhabdomyolysis ( 2 , 5.1 , 7 , 12.3 )', u'Drug Plasma Concentration Increased by Itraconazole', u'Phenytoin', u'NA \xe2\u20ac\u201c Not available/reported', u'\xe2\u2020\u201c = Decreased (induces lamotrigine gluronidation). \xe2\u2020\u2018 = Increased (inhibits lamotrigine glucuronidation). ? = Conflicting data.', u'C max of Stavudine (95% CI)', u'C max of Coadministered Drug (95% CI)', u'*Results based on in vivo clinical studies generally following repeat oral dosing with 200 mg q12h voriconazole to healthy subjects **Results based on in vivo clinical study following repeat oral dosing with 400 mg q12h for 1 day, then 200 mg q12h for at least 2 days voriconazole to healthy subjects *** Non-Nucleoside Reverse Transcriptase Inhibitors', u'*Results based on in vivo clinical studies generally following repeat oral dosing with 200 mg BID voriconazole to healthy subjects **Results based on in vivo clinical study following repeat oral dosing with 400 mg q12h for 1 day, then 200 mg q12h for at least 2 days voriconazole to healthy subjects *** Results based on in vivo clinical study following repeat oral dosing with 400 mg q12h for 1 day, then 200 mg q12h for 4 days voriconazole to subjects receiving a methadone maintenance dose (30 to 100 mg QD) **** Non-Steroidal Anti-Inflammatory Drug ***** Non-Nucleoside Reverse Transcriptase Inhibitors', u'Astemizole Rifabutin Tacrolimus Short-acting benzodiazepines', u'C max', u'Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis ( 2.3 5.1, 7 , 12.3 )', u'Frequent monitoring for adverse events and toxicity related to NSAIDs. Dose reduction of NSAIDs may be needed. [ see Drug Interactions ( 7 ) ].', u'Frequent monitoring for adverse events and toxicity related to calcium channel blockers. Adjustment of calcium channel blocker dosage may be needed.', u'Drugs That May Decrease Serum TBG Concentration', u'Examples of Drugs Within Class', u'\xe2\u2020\u201c= Decreased (induces lamotrigine glucuronidation).', u'norfloxacin']